Novamind is a Toronto-based mental health company that was founded in 2019 with the mission to facilitate safe, legal access to psychedelics.
The company runs two main operations: 1) a national network of psychiatry clinics specializing in integrative psychedelic and alternative therapies and 2) a co-located full-service contract research organization called Cedar Clinical Research Center. Cedar is the first of its kind, leading clinical studies in emerging therapies and psychedelic medicine for esteemed academic institutions and major pharmaceutical companies.
Led by Novamind Chief Medical Officer Dr. Reid Robison, the company’s clinics offer a variety of mental health treatments and services in addition to psychedelic-assisted therapy, including Transcranial magnetic stimulation (TMS) and Eye-Movement Desensitization and Reprocessing. Novamind’s Murray, Utah based clinic is launching the Psychedelic Palliative Care program, which will serve patients facing serious and chronic illness and their families. The program will help establish the infrastructure for future studies using psilocybin. Novamind has also partnered with the Wholeness Center to deliver ketamine-assisted psychotherapy to frontline workers experiencing stress related to the COVID-19 pandemic. The company’s intravenous ketamine treatment for treatment-resistant depression has been approved for insurance coverage by four major payors.
Cedar Clinical Research Center assists with study design, recruitment and screening, data collection and patient management. Its clinical trials have included research into the treatment of PTSD, anxiety, eating disorders, depression, suicidal ideation, and schizophrenia with psychedelics and psychedelic-adjacent drugs such as psilocybin, ketamine, and MDMA.
Novamind went public on the Canadian Securities Exchange in January 2021.